How does cosentyx's mechanism of action differ from biosimilars?

How does Cosentyx's mechanism of action differ from biosimilars?

Cosentyx works by binding directly to interleukin-17A, blocking its interaction with receptors and reducing inflammation in autoimmune conditions. Biosimilars of Cosentyx are not yet available because the drug's patents remain in active enforcement.

Why do biosimilars of Cosentyx not exist yet?

Biologic drugs like Cosentyx have complex structures that require extensive demonstration of analytical similarity, nonclinical similarity, and clinical similarity to gain approval. Regulatory agencies require this three similarity tier approach before any biosimilar can enter the market. Regulators also require matching in all aspects of recommended use, including indications, dosing, and route of administration.

What conditions do Cosentyx and its potential biosimilars treat?

Cosentyx treats plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa. The indications for any approved biosimilar must match exactly or fall under the shared scientific justification for extrapolation.

When does Cosentyx's patent expire?

Cosentyx's primary composition-of-matter patent expires in 2027 in the U.S., with additional patents covering formulations and methods of use that may provide protection through 2030. [1]

How are biosimilars tested for similarity to Cosentyx?

Biosimilars undergo extensive analytical characterization using sensitive methods to show no clinically meaningful differences from the reference product. They also undergo nonclinical studies and a clinical study focused on pharmacokinetic similarity and pharmacodynamic similarity. Regulators require a clinical study in one sensitive patient population to demonstrate overall clinical similarity.